P/E ratio for Sarepta Therapeutics (SRPT)
P/E ratio as of May 2024 (TTM): -16.9
According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.9221. At the end of 2022 the company had a P/E ratio of -16.1.
P/E ratio history for Sarepta Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -16.1 | -7.71% |
| 2021 | -17.5 | -27.49% |
| 2020 | -24.1 | 80.9% |
| 2019 | -13.3 | -33.79% |
| 2018 | -20.1 | -72.14% |
| 2017 | -72.3 | 1338.35% |
| 2016 | -5.02 | -32.42% |
| 2015 | -7.43 | 74.15% |
| 2014 | -4.27 | -28.96% |
| 2013 | -6.01 | 19.25% |
| 2012 | -5.04 | -92.16% |
| 2011 | -64.3 | 809.7% |
| 2010 | -7.07 | 25.84% |
| 2009 | -5.62 | 189.28% |
| 2008 | -1.94 | -25.66% |
| 2007 | -2.61 | -55.66% |
| 2006 | -5.89 | -36.84% |
| 2005 | -9.32 | 173.78% |
| 2004 | -3.41 | -59% |
| 2003 | -8.31 | 89.38% |
| 2002 | -4.39 | -52.96% |
| 2001 | -9.32 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 15.3 | -190.20% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -3.89 | -77.00% | 🇺🇸 USA |
 Novavax NVAX | -1.79 | -89.40% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -35.9 | 111.93% | 🇺🇸 USA |
 Insmed INSM | -4.73 | -72.05% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | -5.09 | -69.93% | 🇺🇸 USA |
 Avidity Biosciences RNA | -9.52 | -43.75% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.